Logo image
Feasibility and Efficacy of Sodium Reduction in the Trials of Hypertension Prevention, Phase I
Journal article   Open access   Peer reviewed

Feasibility and Efficacy of Sodium Reduction in the Trials of Hypertension Prevention, Phase I

Shiriki Kumanyika, Patricia Hebert, Jeffrey Cutler, Vera Lasser, Carolyn Sugars, Lyn Steffen-Batey, Amy Brewer, Mary Cameron, Lana Shepek, Nancy Cook, …
Hypertension (Dallas, Tex. 1979), v 22(4), pp 502-512
Oct 1993
PMID: 8406655
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1161/01.hyp.22.4.502View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open
url
https://doi.org/10.1161/01.HYP.22.4.502View
Published, Version of Record (VoR) Open

Abstract

Phase I of the Trials of Hypertension Prevention was a multicenter, randomized trial of the feasibility and efficacy of seven nonpharmacologic interventions, including sodium reduction, in lowering blood pressure in 30- to 54 -year-old individuals with a diastolic blood pressure of 80 to 89 mm Hg. Six centers tested an intervention designed to reduce dietary sodium to 80 mmol (1800 mg)/24 h with a total of 327 active intervention and 417 control subjects. The intervention consisted of eight group and two one-to-one meetings during the first 3 months, followed by less-intensive counseling and support for the duration of the study. The mean net decrease in sodium excretion was 43.9 mmol/24 h at 18 months. Women had lower sodium intake at baseline and were therefore more likely to decrease to less than 80 mmol/24 h. Black subjects were less likely to decrease to less than 80 mmol/d, independent of sex or baseline sodium excretion. The mean (95% confidence interval) net decrease associated with treatment was −2.1 (−3.3, −0.8) mm Hg for systolic blood pressure and −1.2 (−2.0, −0.3) mm Hg for diastolic blood pressure at 18 months (both P<.01). Multivariate analyses indicated a larger systolic blood pressure effect in women (−4.44 versus −1.23 mm Hg in men), adjusted for age, race, baseline blood pressure, and baseline 24-hour urinary sodium excretion (P=.02). Dose-response analyses indicated an adjusted decrease of −1.4 mm Hg for systolic blood pressure and −0.9 mm Hg for diastolic blood pressure for a decrease of 100 mmol/24 h in 18-month sodium excretion. These results support the utility of sodium reduction as a population strategy for hypertension prevention and raise questions about possible differences in dose response associated with gender and initial level of sodium intake.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Peripheral Vascular Disease
Logo image